Solasia Pharma K.K. develops drugs in the field of oncology in Asia. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Solasia Pharma K.K's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 9SO's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 9SO underperformed the German Biotechs industry which returned 1.1% over the past year.
Return vs Market: 9SO underperformed the German Market which returned 2.6% over the past year.
Price Volatility Vs. Market
How volatile is Solasia Pharma K.K's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Solasia Pharma K.K undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 9SO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 9SO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 9SO is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: 9SO is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 9SO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 9SO is good value based on its PB Ratio (3x) compared to the DE Biotechs industry average (4.4x).
How is Solasia Pharma K.K forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Solasia Pharma K.K has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Solasia Pharma K.K's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Solasia Pharma K.K competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Solasia Pharma K.K performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 9SO is currently unprofitable.
Growing Profit Margin: 9SO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 9SO is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.
Accelerating Growth: Unable to compare 9SO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9SO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.1%).
Return on Equity
High ROE: 9SO has a negative Return on Equity (-36.26%), as it is currently unprofitable.
How is Solasia Pharma K.K's financial position?
Financial Position Analysis
Short Term Liabilities: 9SO's short term assets (¥2.7B) exceed its short term liabilities (¥410.0M).
Long Term Liabilities: 9SO's short term assets (¥2.7B) exceed its long term liabilities (¥77.0M).
Debt to Equity History and Analysis
Debt Level: 9SO is debt free.
Reducing Debt: 9SO has no debt compared to 5 years ago when its debt to equity ratio was 334.6%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9SO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 9SO is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.
What is Solasia Pharma K.K current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 9SO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 9SO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 9SO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 9SO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 9SO's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Yoshihiro Arai (60 yo)
Mr. Yoshihiro Arai has been the President and Representative Director at Solasia Pharma KK since February 2013. Mr. Arai served as Executive Vice President of Development of Solasia Pharma K.K. (formerly k ...
|President & Representative Director||7.67yrs||no data||0.45% |
|CFO, GM & Director||4.83yrs||no data||0.35% |
|0.58yr||no data||no data|
|External Corporate Auditor||no data||no data||no data|
|Independent Outside Director||no data||no data||no data|
|Independent Outside Director||4.42yrs||no data||no data|
|Statutory Auditor||1.75yrs||no data||no data|
|Independent Outside Director||0.58yr||no data||no data|
Experienced Board: 9SO's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.4%.
Solasia Pharma K.K.'s company bio, employee growth, exchange listings and data sources
- Name: Solasia Pharma K.K.
- Ticker: 9SO
- Exchange: DB
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥17.392b
- Listing Market Cap: JP¥139.275m
- Shares outstanding: 119.95m
- Website: https://www.solasia.co.jp
Number of Employees
- Solasia Pharma K.K.
- Sumitomo Fudosan Shiba-Koen Tower
- 4th Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|4597||TSE (The Tokyo Stock Exchange)||Yes||Common Shares||JP||JPY||Mar 2017|
|9SO||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 2017|
Solasia Pharma K.K. develops drugs in the field of oncology in Asia. The company offers episil oral liquid for the control and relief of pain; and Sancuso, a transdermal delivery system that delivers grani ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/20 21:50|
|End of Day Share Price||2020/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.